Omburtamab I-131

Unassigned

New Medicines

Neuroblastoma in children

Information

New molecular entity
Y-mAbs Therapeutics
Y-mAbs Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Theranostic monoclonal antibody 8H9, conjugated to to 131 iodine. The antibody 8H9 acts by targeting B7-H3 or CD276 receptors present on cancer cells, causing radiolabelled iodine to kill cancerous tumours.
Neuroblastoma represents about 10% of solid tumors in infants and children under the age of 15, with an annual incidence of about 1/70,000 in children in this class of age [1].
Neuroblastoma in children
Intracerebral

Evidence based evaluations